NOCRI appears on Cambridge TV following a new clinical trail

The TRANSFORM–UK study into a possible new treatment for pulmonary arterial hypertension (PAH) is a partnership between the NIHR Rare Diseases Translational Research Collaboration and the global pharmaceutical company Roche.
PAH is a progressive disease caused by narrowing or tightening of the pulmonary arteries, which connect the heart to the lungs. This results in the right side of the heart becoming enlarged due to the increased strain of pumping blood through the lungs.
Strain on the heart and decrease in blood circulation through the lungs lead to the common symptoms of PAH including breathlessness, fatigue, weakness and angina.
Fewer than 40% of patients currently live beyond five years after diagnosis and there is no cure.
The study is being led by Dr Mark Toshner from the Papworth Hospital NHS Foundation Trust and is hosted by Cambridge University Hospitals NHS Trust.
Cambridge TV has interviewed Dr Mark Toshner and Dr Matthew Hallsworth, Head of External Relations, NIHR Office for Clinical Research Infrastructure (NOCRI), about the study.
You can see the full interview on the following click the following link